Further support for this conclusion was obtained by the lack of additive or synergistic inhibition of pro-fibrotic markers in SSc fibroblasts treated with an EZH2/PRC2 inhibitor and an LSD1 inhibitor. Here, EZH2 is linked to systemic sclerosis.